Cytogenetic and molecular mechanisms of resistance to imatinib

Seminars in Hematology

Volumn 40, Issue 2 SUPPL. 2, 2003, Pages 69-79

  Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOGENETICS; DRUG RESPONSE; ENZYME ACTIVATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ARTICLE; CELL CLONE; CHROMOSOME ANALYSIS; DISEASE COURSE; DRUG RESISTANCE; GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOLOGY; TREATMENT OUTCOME;

CHROMOSOME ABERRATIONS; CLONE CELLS; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; POINT MUTATION; PYRIMIDINES; RNA, NEOPLASM; TREATMENT OUTCOME;

EID: 0038700994     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2003.50045     Document Type: Conference Paper

References (57)

1. Barthe C, Cony-Makhoul P, Melo JV, et al: Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a, 2001
2. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
3. Branford S, Rudzki Z, Walsh S, et al: Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivec non-responsive cases of CML. Blood 98:769a-770a, 2001 (suppl 1, abstr)
4. Buchdunger, E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
5. Burchert A, Wölfl S, Schmidt M, et al: Interferon α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101:259-264, 2002
6. Chase A, Huntly BJP, Cross NCP: Cytogenetics of chronic myeloid leukemia. Best Pract Res Clin Haematol 14:553-571, 2001
7. Corbin AS, Buchdunger E, Pascal F, et al: Analysis of the structural basis of specificity of STI571 binding to the Abl kinase domain. J Biol Chem 277:32214-32219, 2002
8. Cross NCP, Feng L, Bungey J, et al: Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 11:39-43, 1993 (suppl)
9. Cross NCP, Melo JV, Feng L, et al: An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8:186-189, 1994
10. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
11. Druker BJ, Talpaz M, Resta, DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
12. Duesberg P, Stindl R, Hehlmann R: Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortment catalyzed by aneuploidy. Proc Natl Acad Sci USA 98:11283-11288. 2001
13. Emig M, Saussele S, Wittor H, et al: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13:1825-1832, 1999
14. Gambacorti-Passerini C, Barni R, le Coutre P, et al: Role of al acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst 92:1641-1650, 2000
15. Gambacorti-Passerini C, le Coutre P, Zucchetti M, et al: Binding of imatinib by alpha(1)-acid glycoprotein. Blood 100:367-368, 2002
16. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
17. Griffin JD: Resistance to targeted therapy in leukaemia. Lancet 359:458-459, 2002
18. Heaney C, Kolibaba K, Bhat A, et al: Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 89:297-306, 1997
19. Hochhaus A, Kreil S, Corbin A, et al: Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a, 2001
20. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196, 2002
21. Hofmann WK, de Vos S, Elashoff D, et al: Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study. Lancet 359:481-486, 2002
22. + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860-1862, 2002
23. Hoover RR, Mahon FX, Melo JV, et al: Overcoming STI571 resistance with the farnesyl tarnsferase inhibitor SCH66336. Blood 100:1068-1071, 2002
24. Kano Y, Akutsu M, Tsunoda S, et al: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007, 2001
25. Kantarjian H, Sawyers C, Hochhaus A, et al: Imatinib mesylate (Gleevec™) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: Results of a phase II study. N Engl J Med 346:645-652, 2002
26. Kantarjian HM, Cortes JE, Rowe JM, et al: Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Semin Hematol 39:36-38, 2002 (suppl)
27. Kantarjian HM, Talpaz M, O'Brien S, et al: Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. Blood 101:473-475, 2003
28. Keating, A. Chronic myeloid leukemia: Current therapies and the potential role of farnesyltransferase inhibitors. Semin Hematol 39:11-17, 2002 (suppl)
29. La Rosée P, Johnson K, O'Dwyer ME, et al: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30:729-737, 2002
30. La Rosée P, O'Dwyer ME, Druker BJ: Insights from preclinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec™/Glivec®) in chronic myelogenous leukemia: A translational perspective. Leukemia 16:1213-1219, 2002
31. le Coutre P, Kreuzer KA, Na IK, et al: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 28:75-85, 2002
32. le Coutre P, Tassi E, Varella-Garcia M, et al: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758-1766, 2000
33. Luzzatto L, Frassoni F, Melo JV: Imatinib: Can one outwit chronic myeloid leukemia? Haematologica 87:898-901, 2002
34. Mahon FX, Deininger MWN, Schultheis B, et al: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 96:1070-1079, 2000
35. Melo JV: The molecular biology of chronic myeloid leukaemia. Leukemia 10:751-756, 1996
36. Merx K, Müller MC, Kreil S, et al: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16:1579-1583, 2002
37. Nichols GL, Raines MA, Vera JC, et al: Identification of CRKL as the constitutively phosphorylated 39- kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 84:2912-2918, 1994
38. Oda T, Heaney C, Hagopian JR, et al: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925-22928, 1994
39. Roche-Lestienne C, Soenen-Comu V, Grardel-Duflos N, et al: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they pre-exist to the onset of treatment. Blood 100:1014-1018, 2002
40. Roumiantsev S, Shah NP, Gorre ME, et al: Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99:10700-10705, 2002
41. Saraste M, Sibbald PR, Wittinghofer A: The P-loop - A common motif in ATP- and GTP-binding proteins. Trends Biochem Sci 15:430-434, 1990
42. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340:1330-1340, 1999
43. Sawyers CL, Hochhaus A, Feldman E, et al: Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002
44. Scappini B, Onida F, Kantarjian HM, et al: In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94:2653-2662, 2002
45. Schindler T, Bornmann W, Pellicena P, et al: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938-1942, 2000
46. Schoch C, Schnittger S, Bursch S, et al: Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia 16:53-59, 2002
47. Senechal K, Heaney C, Druker B, et al: Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol 18:5082-5090, 1998
48. Shah NP, Nicoll JM, Gorre ME, et al: Resistance to Gleevec: Sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and de novo-resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis. Blood 98:770a. 2001 (suppl 1, abstr)
49. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
50. Talpaz M, Silver RT, Druker BJ, et al: Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase II study. Blood 99:1928-1937, 2002
51. + leukemia. Blood 84:1731-1736, 1994
52. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al: Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 96:3195-3199, 2000
53. Tipping AJ, Mahon FX, Lagarde V, et al: Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 98:3864-3867, 2001
54. Topaly J, Zeller W, Fruehauf S: Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342-347, 2001
55. von Bubnoff N, Schneller F, Peschel C, et al: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359:487-491, 2002
56. Warmuth M, Simon N, Mitina O, et al: Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing STI571 resistant Bcr/Abl kinases. Blood 101:664-672, 2003
57. Weisberg E, Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95:3498-3505, 2000